Dashboard
Portfolios
Watchlist
Community
Discover
Screener
Community
/
Hong Kong
/
Pharmaceuticals & Biotech
/
Everest Medicines
1952
Everest Medicines
NRDL Approval And Pipeline Efforts Will Counterbalance Potential Risks
AN
AnalystConsensusTarget
Not Invested
Consensus Narrative from 8 Analysts
Published
30 Mar 25
Updated
14 Aug 25
0
Set Fair Value
0
votes
Share
AnalystConsensusTarget
's Fair Value
HK$55.53
25.4% overvalued
intrinsic discount
14 Aug
HK$69.65
Loading
1Y
272.1%
7D
-1.3%
Author's Valuation
HK$55.5
25.4% overvalued
intrinsic discount
AnalystConsensusTarget Fair Value
View Valuation
Narrative
Updates
1
Shared on
02 Apr 25
Fair value Increased 0.81%
Read more
0
votes
Share
Valuator
Company Info
Notes
AnalystConsensusTarget Fair Value
HK$55.5
25.4% overvalued
intrinsic discount
Future estimation in
3 Years
time period
Past
Future
-5b
3b
2018
2020
2022
2024
2025
2026
2028
Revenue CN¥2.6b
Earnings CN¥351.7m
Revenue
Profit Margin
Future PE
Revenue
% p.a.
0
Decrease
Increase
Current revenue growth rate
30.49%
Biotech revenue growth rate
11.97%
Other Inputs & Calculation
Risk Level (Discount Rate)
Our default considers factors like the company's size, volatility, profitablity and country of operation.
Risk Level (Discount Rate)
%
0
Decrease
Increase
Current discount rate
6.89%
Calculation
CN¥351.69m
Earnings '28
x
57.18x
PE Ratio '28
=
CN¥20.11b
Market Cap '28
CN¥20.11b
Market Cap '28
/
324.35m
No. shares '28
=
CN¥62.00
Share Price '28
CN¥62.00
Share Price '28
Discounted to 2025 @ 6.89% p.a.
=
CN¥50.77
Fair Value '25
CN¥50.77
Fair Value '25
Converted to HKD @ 1.0937 CNY/HKD Exchange Rate
=
HK$55.53
Fair Value '25